arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Syndax Pharmaceuticals Inc

SNDX
$17.64 ▼ -0.55 (-3.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
48 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

Syndax Pharmaceuticals Inc faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.6B
Dividend Yield
Revenue Growth 91.8%
Op. Margin -54.9%
ROIC -209.3%
FCF / Share $-0.34
Trailing P/E
Price / Book 104.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

48-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$72.79M
↑ +91.8%
Net Income Profit after all expenses
$-42.67M
↑ +49.7%
Operating Margin Operating profit as % of sales
-54.9%
↓ -4.2% 1th
FCF / Share Free cash flow per share
$-0.34
↑ +40.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Cash Quality
70

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 13 years · 48 quarters